(Q36374315)

13 August 2017

Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma (English)

1 reference

13 August 2017

Jae Huh

7

0 references

Dennis Chi

10

object named as

Dennis S Chi

1 reference

13 August 2017

9

Richard R Barakat

1 reference

13 August 2017

3

Nadeem R Abu-Rustum

1 reference

13 August 2017

5

Aileen Caceres

1 reference

13 August 2017

1

Wayne A McCreath

1 reference

13 August 2017

2

Eric L Eisenhauer

1 reference

13 August 2017

Ennapadam S Venkatraman

4

1 reference

13 August 2017

Rachel Bier

6

1 reference

13 August 2017

Jae Cho

8

1 reference

13 August 2017

language of work or name

English

0 references

publication date

20 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

102

1 reference

13 August 2017

1

1 reference

13 August 2017

8-14

1 reference

An opinion in support of second-look surgery in ovarian cancer

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Second-look surgery in the management of epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Long-term follow-up of women with ovarian cancer after positive second-look laparotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.11.040

10.1016/J.YGYNO.2005.11.040

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference